Wells Fargo analyst David Maris says he’s hopeful that Allergan shareholders voting in favor of a combined CEO/Chairman role “marks a turn of the distractive narrative” from break-up speculation to a focus on longer-term execution and pipeline. After speaking with a number of dermatologists and cosmetic surgeons in recent weeks, Maris fells optimistic about U.S. aesthetic market growth in Q1. The analyst maintains an Outperform rating on Allergan shares into the company’s Q1 results on May 7.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.